# FLETCHER D-PRIZE COMPETITION

2024-25 Academic Year

## **Health Access Challenges**

# Increasing demand for Voluntary Medical Male Circumcision (VMMC)

We challenge you to design a new social enterprise that reduces the risk of HIV acquisition for men by generating demand for Voluntary Medical Male Circumcision (VMMC). Fletcher D-Prize will award up to \$20,000 to teams with a plan to launch a pilot of this work, and who have a vision to drive 100,000 procedures within five years and scale country-wide.

#### The Poverty Problem

UNAIDS estimates that 1.4 million new HIV infections occurred in sub-Saharan Africa in 2015, out of 2.1 million new infections globally. New infections among people aged 15 and over are particularly prevalent in Eastern and Southern Africa.

Furthermore, human papillomavirus (HPV), a common sexually-transmitted virus, is the cause of almost all cases of cervical cancer.<sup>3</sup> In sub-Saharan Africa in 2016, cervical cancer caused an estimated 2.1% of total deaths among women 15-49 years old,<sup>4</sup> and an estimated 4.3% of total deaths among women 50-69 years old.<sup>5</sup>

#### The Proven Intervention

VMMC is the voluntary surgical removal of the foreskin of the penis.<sup>6</sup> A meta-analysis of three large randomized controlled trials of VMMC in Eastern and Southern Africa found that men who had participated in the program had a 54% reduction<sup>7</sup> in their risk of acquiring HIV during the

<sup>&</sup>lt;sup>1</sup> UNAIDS Global AIDS Update 2016, Pg 2. http://www.who.int/hiv/pub/arv/global-AIDS-update-2016 en.pdf

<sup>&</sup>lt;sup>2</sup> UNAIDS Global AIDS Update 2016, Pg 6. http://www.who.int/hiv/pub/arv/global-AIDS-update-2016 en.pdf

<sup>&</sup>lt;sup>3</sup> Centers for Disease Control and Prevention – What Are the Risk Factors for Cervical Cancer? – 2014: https://www.cdc.gov/cancer/cervical/basic\_info/risk\_factors.htm

<sup>&</sup>lt;sup>4</sup> Institute of Health Metrics and Evaluation: GBD Compare 2016: <a href="http://ihmeuw.org/478q">http://ihmeuw.org/478q</a>

<sup>&</sup>lt;sup>5</sup> Institute of Health Metrics and Evaluation: GBD Compare 2016: http://ihmeuw.org/478t

<sup>&</sup>lt;sup>6</sup> World Health Organization - Voluntary Medical Male Circumcision for HIV Prevention Factsheet – 2012: http://www.who.int/hiv/topics/malecircumcision/fact\_sheet/en/

<sup>&</sup>lt;sup>7</sup> 95% confidence interval: 38%-76%

first 21 to 24 months after circumcision.<sup>8</sup> Based on this evidence, WHO and UNAIDS have recommending scaling-up VMMC in countries with high rates of HIV transmission among heterosexual couples and low baseline rates of male circumcision.<sup>9</sup> WHO's fourteen "priority countries" for scale-up are Botswana, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.<sup>10</sup>

One randomized controlled trial in Uganda found that partners of men who participated in a VMMC program had a 23% reduction<sup>11</sup> in their risk of acquiring high-risk HPV over a two-year period.<sup>12</sup>

It's important to note that condom use after male circumcision is essential for HIV prevention. Another randomized controlled trial in Uganda found that circumcision of HIV-infected men did not reduce HIV transmission to female partners over 24 months before it was stopped early due to futility.<sup>13</sup>

More detailed information on this program is available in GiveWell's VMMC intervention report.

#### Your Distribution Challenge

Fletcher D-Prize will award up to \$20,000 to a team that can create a new organization that motivates men to undergo a VMMC procedure, who otherwise would not.

You must have a vision to mobilize 100,000 men for treatment within five years. Our award is meant to enable the first step toward this vision by supporting a small test pilot of your idea, that targets anywhere from 100-250 men, and connects them to existing treatment options.

#### Designing Your Social Enterprise

We believe a successful distribution entrepreneur must have compelling answers to the following questions:

- (1) Why is this intervention appropriate for your local market? A successful proposal will operate in one of the fourteen priority countries for VMMC scale-up mentioned above. We highly recommend you target a local region where VMMC treatment rates are the lowest.
- (2) How will your model create demand for VMMC among patients, and connect them to existing service providers? There are many local NGOs and health service providers that already exist and can perform this specific treatment. Your model should seek to cooperate with these

<sup>&</sup>lt;sup>8</sup> Siegfried et al. 2009. Male circumcision for prevention of heterosexual acquisition of HIV in men. http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD003362.pub2/full

<sup>&</sup>lt;sup>9</sup> World Health Organization - Voluntary Medical Male Circumcision for HIV Prevention Factsheet – 2012: http://www.who.int/hiv/topics/malecircumcision/fact\_sheet/en/

<sup>&</sup>lt;sup>10</sup> World Health Organization - Voluntary Medical Male Circumcision for HIV Prevention Factsheet – 2012: http://www.who.int/hiv/topics/malecircumcision/fact\_sheet/en/

 $<sup>^{11}</sup>$  95% confidence interval: 7%-37%

<sup>&</sup>lt;sup>12</sup> Wawer et al. 2011: Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda: <a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61967-8/abstract">http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61967-8/abstract</a>

<sup>&</sup>lt;sup>13</sup> Wawer et al. 2009. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. <a href="https://pubmed.ncbi.nlm.nih.gov/19616720/">https://pubmed.ncbi.nlm.nih.gov/19616720/</a>

existing resources by focusing on generating demand.

It is <u>absolutely critical</u> that patients elect to have VMMC *voluntarily*. Your proposal should specifically address how you will ensure there is no coercion among patient outreach. A proposal that fails to adequately address this concern will not be funded.

- (3) How will you measure the marginal impact of your work? One challenge will be proving your work leads to marginal or incremental impact. Said another way, you must prove that your model led to more uncircumcised men voluntarily completing circumcision than if your organization did not exist.
  - You will most likely have to track this data yourself, as in most operating regions there is not existing data gathering and reporting.
  - During the early pilot stage, you should consider a process for tracking impact that is simple and efficient. For example you could collect data from local health authorities and show that 90% of men in a local area received treatment after your pilot compared to historical baseline data (which is likely 50% or lower coverage). Or alternatively, you could show 90% coverage in your pilot region compared to a lower (50% or lower) coverage in a neighboring area. Regardless of your plan, simply tracking how many men voluntarily elected for VMMC is not enough to prove incremental impact.
  - As you grow, you will need to consider more robust measurement processes, including understanding the long-term impact of your work on local HIV rates.
- (4) Can your operation scale? We seek ideas that will result in a massive increase in the number of voluntary candidates for VMMC who would otherwise not pursue treatment, with a plan to scale up and target a larger region of 100,000 VMMC candidates nationwide within five years. You should explain your vision to reach this target.

The ideal social enterprise will have a plan to raise significant funding to scale, either through investment or philanthropy.

### Ready To Apply?

Download a First Round Application Packet and start creating your proposal at <a href="https://sites.tufts.edu/dprize/">https://sites.tufts.edu/dprize/</a>.

Questions? Email Kaushik Chaudhuri at <a href="mailto:Kaushik.Chaudhuri@tufts.edu">Kaushik.Chaudhuri@tufts.edu</a>.